CA2989145C - IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES - Google Patents

IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES

Info

Publication number
CA2989145C
CA2989145C CA2989145A CA2989145A CA2989145C CA 2989145 C CA2989145 C CA 2989145C CA 2989145 A CA2989145 A CA 2989145A CA 2989145 A CA2989145 A CA 2989145A CA 2989145 C CA2989145 C CA 2989145C
Authority
CA
Canada
Prior art keywords
dfx
composition
poly
pharmaceutical composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2989145A
Other languages
English (en)
French (fr)
Other versions
CA2989145A1 (en
Inventor
Dave A. Miller
Justin M. Keen
Sandra U. KUCERA
Original Assignee
Austinpx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austinpx LLC filed Critical Austinpx LLC
Publication of CA2989145A1 publication Critical patent/CA2989145A1/en
Application granted granted Critical
Publication of CA2989145C publication Critical patent/CA2989145C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2989145A 2015-06-17 2016-06-17 IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES Active CA2989145C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180998P 2015-06-17 2015-06-17
US62/180,998 2015-06-17
PCT/US2016/038089 WO2016205658A1 (en) 2015-06-17 2016-06-17 Improved formulations of deferasirox and methods of making the same

Publications (2)

Publication Number Publication Date
CA2989145A1 CA2989145A1 (en) 2016-12-22
CA2989145C true CA2989145C (en) 2024-10-29

Family

ID=57546755

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2989145A Active CA2989145C (en) 2015-06-17 2016-06-17 IMPROVED DEFERASIROX FORMULATIONS AND THEIR MANUFACTURING PROCESSES

Country Status (10)

Country Link
US (4) US10265301B2 (https=)
EP (1) EP3310354B1 (https=)
JP (1) JP2018517734A (https=)
CN (1) CN107847490A (https=)
AU (3) AU2016280280B2 (https=)
CA (1) CA2989145C (https=)
HK (1) HK1254608A1 (https=)
IL (1) IL256322B (https=)
MA (1) MA43271A (https=)
WO (1) WO2016205658A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565279B1 (en) 2007-12-05 2014-12-03 Complete Genomics, Inc. Efficient base determination in sequencing reactions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2977455B1 (en) 2009-06-15 2020-04-15 Complete Genomics, Inc. Method for long fragment read sequencing
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
WO2020061474A1 (en) * 2018-09-20 2020-03-26 Tautona Group Ip Holding Company, L.L.C. Iron chelating compounds for treating aesthetic skin conditions
EP4096791A1 (en) 2020-01-31 2022-12-07 Nanocopoeia LLC Amorphous nilotinib microparticles and uses thereof
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN112870361A (zh) * 2021-01-28 2021-06-01 重庆医科大学 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用
CN116203161A (zh) * 2022-05-30 2023-06-02 上海奥科达医药科技股份有限公司 地拉罗司颗粒剂中相关杂质的检测方法
WO2025151876A1 (en) * 2024-01-11 2025-07-17 Minneamrita Therapeutics Llc Triptolide formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
BRPI0617715A2 (pt) * 2005-10-19 2011-08-02 Novartis Ag comprimidos dispersìveis compreendendo deferasirox
JP6073043B2 (ja) 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
WO2009067557A1 (en) * 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
AU2010329487A1 (en) * 2009-12-07 2012-06-14 Mapi Pharma Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
ES2543427T3 (es) 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
WO2012025935A2 (en) * 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
MX2013003522A (es) 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
WO2012116238A1 (en) * 2011-02-23 2012-08-30 Dispersol Technologies, Llc PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
HRP20190173T1 (hr) 2013-03-08 2019-03-22 Novartis Ag Oralne formulacije deferasiroksa
US20160120847A1 (en) 2013-05-10 2016-05-05 Cipla Limited Low Dose Pharmaceutical Composition

Also Published As

Publication number Publication date
CN107847490A (zh) 2018-03-27
AU2016280280A1 (en) 2018-01-04
US20190167643A1 (en) 2019-06-06
MA43271A (fr) 2018-09-26
US20240091201A1 (en) 2024-03-21
IL256322B (en) 2022-03-01
AU2021277731A1 (en) 2021-12-23
AU2024202528B2 (en) 2026-01-08
EP3310354A1 (en) 2018-04-25
IL256322A (en) 2018-02-28
EP3310354C0 (en) 2026-02-25
CA2989145A1 (en) 2016-12-22
EP3310354A4 (en) 2018-12-12
AU2024202528A1 (en) 2024-05-09
HK1254608A1 (zh) 2019-07-26
EP3310354B1 (en) 2026-02-25
JP2018517734A (ja) 2018-07-05
US10258608B2 (en) 2019-04-16
US11878005B2 (en) 2024-01-23
AU2021277731B2 (en) 2024-04-11
AU2016280280B2 (en) 2021-09-02
US10265301B2 (en) 2019-04-23
WO2016205658A1 (en) 2016-12-22
US20170296514A1 (en) 2017-10-19
US20170027911A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
AU2024202528B2 (en) Improved formulations of deferasirox and methods of making the same
US11679105B1 (en) Pharmaceutical compositions of cabozantinib
WO2012116238A1 (en) PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS
CA3022878C (en) Improved drug formulations
BR112014011981B1 (pt) FORMULAgOES FARMACEUTICAS SOLIDAS ORAIS, SEUS PROCESSOS DE PREPARAgAO E USOS
JP2010513356A (ja) ニューロキニンアンタゴニストを含む製剤
US20250360085A1 (en) Improved drug formulations
US20190015412A1 (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
CN107693516B (zh) 一种地拉罗司药物组合物及其药物制剂、制备方法和用途
EP2953615A1 (en) Solid dispersion comprising amorphous cilostazol
US20250352482A1 (en) Amorphous dosage form containing ebselen

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210520

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20241023

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20241029

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610